Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]

Authors Pecenak J, Novotny V

Received 30 October 2013

Accepted for publication 30 October 2013

Published 26 November 2013 Volume 2013:9 Pages 1827—1828

DOI https://doi.org/10.2147/NDT.S56808

Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.

On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current study was much higher than in the 6-week and 8-week double-blind, placebo-controlled studies of agomelatine13,36 and higher than in an observational study of different antidepressants where a 38.2% early remission rate and a 20.5% early response rate were found at week 6 of treatment,41 but similar to a double-blind study comparing agomelatine with fluoxetine in patients with severe depression."42

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]